Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $506,680 | $122,880 | $591,681 | $2,325,645 |
| - Cash | $99,500 | $111,700 | $642,600 | $576,100 |
| + Debt | $676,100 | $860,200 | $1,405,800 | $841,000 |
| Enterprise Value | $1,083,280 | $871,380 | $1,354,881 | $2,590,545 |
| Revenue | $1,043,600 | $1,049,300 | $1,117,500 | $1,773,600 |
| % Growth | -0.5% | -6.1% | -37% | – |
| Gross Profit | $375,400 | $360,000 | $473,000 | $793,200 |
| % Margin | 36% | 34.3% | 42.3% | 44.7% |
| EBITDA | $53,400 | -$47,000 | $15,700 | $504,200 |
| % Margin | 5.1% | -4.5% | 1.4% | 28.4% |
| Net Income | -$190,600 | -$760,500 | -$211,600 | $219,500 |
| % Margin | -18.3% | -72.5% | -18.9% | 12.4% |
| EPS Diluted | -3.6 | -14.85 | -4.47 | 4.06 |
| % Growth | 75.8% | -232.2% | -210.1% | – |
| Operating Cash Flow | $58,700 | -$206,300 | -$34,100 | $321,100 |
| Capital Expenditures | -$22,900 | -$51,600 | -$115,800 | -$225,000 |
| Free Cash Flow | $35,800 | -$257,900 | -$149,900 | $96,100 |